TABLE 1.

Number of past VL cases per period, where the cases were treated, and antileishmania drug received

Time between VL treatment and November 2006 blood sampling (no. of subjects)% (no.) of cases treated by facilitya:% (no.) of cases treated withd:% (no.) of cases positive bye:
GovernmentbPrivate/NGOcSSGAmphotericin BDATrK39 ELISA
<1 yr (124)19.4 (24)80.6 (100)31.5 (39)61.3 (76)93.5 (116)86.3 (107)
1-<5 yr (447)16.1 (72)83.7 (374)38.0 (170)55.9 (250)89.3 (399)68.2 (305)
5-<10 yr (123)13.0 (16)87.0 (107)53.7 (66)45.5 (56)80.5 (99)57.7 (71)
10-<15 yr (35)25.7 (9)74.3 (26)68.6 (24)31.4 (11)68.6 (24)42.9 (15)
≥15 yr (51)29.4 (15)62.7 (32)84.3 (43)7.8 (4)52.9 (27)39.2 (20)
  • a Other sites and “unknown” not shown.

  • b District Hospital, Medical College, and Community Health Centres.

  • c Private hospitals or health centers and nongovernmental organizations (NGO; i.e., Kala Azar Medical Research Centre in Muzaffapur).

  • d Other drugs (i.e., miltefosine) and “unknown” not shown. SSG, sodium stibogluconate.

  • e Cutoff values: DAT, titer of 1:3,200; rK39 ELISA, 22% positivity.